FAST READ
- — read only this box if short on time
- Union MoS Jitendra Singh launched BIO-NIVESH in **New Delhi.
- Purpose**: connect biotechnology/deep-tech startups with investors and mobilise private capital for scale-up.
- The inaugural edition brought together 20 startups and around 50 investors.
- Selection considered innovation, development stage, market potential, scalability and regulatory readiness.
- It is designed as a two-way engagement, not merely a startup pitching event.
WHY IN NEWS
- BIO-NIVESH was launched at a joint roundtable of biotechnology startups and investors.
- Biotech firms often face a financing gap between scientific proof and commercial scale.
- The platform seeks to connect science, capital, industry and markets more systematically.
TOP DATA & FACTS
- Launch location: New Delhi.
- Launched by Union MoS (Independent **Charge) Dr Jitendra Singh.
- Initial startups**: 20.
- Approximate investors: 50.
- Biotechnology commercialisation often requires long validation cycles.
- Regulatory readiness matters in health, agriculture and industrial biotech.
- Deep-tech ventures generally need more patient capital than ordinary software startups.
- Scale-up may require pilot plants, clinical validation or manufacturing certification.
- Investor understanding of scientific risk is critical.
- Government can reduce information gaps without choosing commercial winners blindly.
HISTORICAL PERSPECTIVE
- India built biotechnology capacity through public laboratories, universities and a growing biopharma sector.
- Biotechnology entrepreneurship expanded with incubators and dedicated innovation funding.
- The startup ecosystem broadened from digital services into deep technology.
- COVID-19 highlighted the strategic value of domestic biotech capability.
- Recent policy increasingly focuses on translating research into products.
ECONOMIC PERSPECTIVE
- Biotech innovation can generate high-value intellectual property and manufacturing.